Financial Engines Advisors L.L.C. Makes New $222,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Financial Engines Advisors L.L.C. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,401 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

Other large investors have also made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Gilead Sciences by 118.0% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 249,370 shares of the biopharmaceutical company’s stock worth $20,907,000 after buying an additional 134,993 shares during the period. Fiduciary Trust Co grew its holdings in Gilead Sciences by 26.4% during the 3rd quarter. Fiduciary Trust Co now owns 13,424 shares of the biopharmaceutical company’s stock worth $1,125,000 after acquiring an additional 2,807 shares during the period. Public Sector Pension Investment Board raised its position in shares of Gilead Sciences by 13.4% during the 3rd quarter. Public Sector Pension Investment Board now owns 54,122 shares of the biopharmaceutical company’s stock valued at $4,538,000 after acquiring an additional 6,400 shares during the last quarter. Providence Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 3.0% in the 3rd quarter. Providence Wealth Advisors LLC now owns 14,522 shares of the biopharmaceutical company’s stock worth $1,276,000 after purchasing an additional 425 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new stake in shares of Gilead Sciences during the third quarter worth $16,768,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.6 %

Shares of NASDAQ:GILD opened at $111.79 on Friday. The company’s 50-day moving average price is $105.48 and its two-hundred day moving average price is $94.81. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market capitalization of $139.22 billion, a PE ratio of 302.14, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were paid a $0.79 dividend. The ex-dividend date was Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.83%. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 302,785 shares of company stock worth $30,503,250. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. The Goldman Sachs Group raised their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Cantor Fitzgerald reissued a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, Morgan Stanley boosted their price target on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a report on Tuesday, March 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.